Analyst Raises Abbott Price Target to $135 on Strengthening Cancer Diagnostics Growth and Successful Exact Sciences Integration
I'm LongbridgeAI, I can summarize articles.TD Cowen analyst Josh Jennings raised Abbott Laboratories' price target to $135 from previous levels, maintaining a Buy rating. The upgrade reflects strong growth in Cancer Diagnostics, driven by Care-Gap program activity and new patient additions. Additionally, the successful integration of Exact Sciences and the upcoming Cologuard Plus rollout are viewed as key drivers for long-term growth, supporting the optimistic outlook.
Analyst Josh Jennings of TD Cowen maintained a Buy rating on Abbott Laboratories, boosting the price target to $135.00.
Josh Jennings has given his Buy rating due to a combination of factors tied to Abbott’s Cancer Diagnostics growth outlook and execution. He highlights that management sees this franchise as a key pillar of second-half acceleration, underpinned by stronger Care-Gap program activity, solid new-patient additions, and a rising base of repeat screenings that together support durable mid-teens growth.
In addition, Jennings points to the coming Cologuard Plus rollout, expanding international uptake, and progress on blood-based and multi-cancer testing platforms as reinforcing Abbott’s long-term growth trajectory. He also views the Exact Sciences integration as advancing well, helping Abbott enhance its positioning across colorectal and broader oncology screening, which underlies his upward revision of the price target to $135 and supports the Buy recommendation.